Trial · NCT01876212
Outcomes20
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Immune Response Rate | Up to 13 months | Patients that received at least one cycle of study treatment. | proportion of participants | NUMBER |
| SECONDARY | Best Clinical Response | Up to 13 months | Patients that received at least once cycle of study treatment who were evaluable for response using tumor measurements via radiologic evaluation. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Objective Response Rate (ORR) | Up to 13 months | Patients that received at least once cycle of study treatment who were evaluable for response using tumor measurements via radiologic evaluation. | proportion of participants | NUMBER |
| SECONDARY | Worst Grade of Any Toxicity | Up to 2 years | Patients that received at least one dose of study treatment who experienced a treatment-related toxicity . | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Progression-free Survival (PFS) | Up to 15 months | Patients that received at least once cycle of study treatment who were evaluable for response using tumor measurements via radiologic evaluation. | months | MEDIAN |
| SECONDARY | Overall Survival (OS) | Up to 30 months | All patients enrolled in the study. | months | MEDIAN |
| SECONDARY | T Cell-recruiting Chemokine CXCL10/IP-10 | At baseline (prior to treatment) | Patients that received Vaccine (Cycle 1, Day 1) + dasatinib (Cycle 2, D1) or Vaccine + dasatinib (both agents beginning Cycle 1, D1) for which there was an analyzable PBMC sample. | pg/mL | MEAN |
| SECONDARY | T Cell-recruiting Chemokine CXCL10/IP-10 | At between 5 and 7 weeks, post treatment | Patients that received Vaccine (Cycle 1, Day 1) + dasatinib (Cycle 2, D1) or Vaccine + dasatinib (both agents beginning Cycle 1, D1) for which there was an analyzable PBMC sample. | pg/mL | MEAN |
| SECONDARY | Treg CD4FoxP3 Suppressor Cells | At baseline (prior to treatment) | Patients that received Vaccine (Cycle 1, Day 1) + dasatinib (Cycle 2, D1) or Vaccine + dasatinib (both agents beginning Cycle 1, D1) for which there was an analyzable PBMC sample. | percentage of cells | MEAN |
| SECONDARY | Treg CD4FoxP3 Suppressor Cells | At between 4 and 6 weeks, post treatment | Patients that received Vaccine (Cycle 1, Day 1) + dasatinib (Cycle 2, D1) or Vaccine + dasatinib (both agents beginning Cycle 1, D1) for which there was an analyzable PBMC sample. | percentage of cells | MEAN |
| SECONDARY | Treg CD4FoxP3 Suppressor Cells | At between 7 and 10 weeks, post treatment | Patients that received Vaccine (Cycle 1, Day 1) + dasatinib (Cycle 2, D1) or Vaccine + dasatinib (both agents beginning Cycle 1, D1) for which there was an analyzable PBMC sample. | percentage of cells | MEAN |
| SECONDARY | Monocytic Myeloid Derived Suppressor Cells (M-MDSC) | At baseline (prior to treatment) | Patients that received Vaccine (Cycle 1, Day 1) + dasatinib (Cycle 2, D1) or Vaccine + dasatinib (both agents beginning Cycle 1, D1) for which there was an analyzable PBMC sample. | percentage of cells | MEAN |
| SECONDARY | Monocytic Myeloid Derived Suppressor Cells (M-MDSC) | At between 4 and 6 weeks, post treatment | Patients that received Vaccine (Cycle 1, Day 1) + dasatinib (Cycle 2, D1) or Vaccine + dasatinib (both agents beginning Cycle 1, D1) for which there was an analyzable PBMC sample. | percentage of cells | MEAN |
| SECONDARY | Monocytic Myeloid Derived Suppressor Cells (M-MDSC) | At between 7 and 10 weeks, post treatment | Patients that received Vaccine (Cycle 1, Day 1) + dasatinib (Cycle 2, D1) or Vaccine + dasatinib (both agents beginning Cycle 1, D1) for which there was an analyzable PBMC sample. | percentage of cells | MEAN |
| SECONDARY | Polymorphonucler Myeloid-derived Suppressor Cells (PMN-MDSC) | At baseline (prior to treatment) | Patients that received Vaccine (Cycle 1, Day 1) + dasatinib (Cycle 2, D1) or Vaccine + dasatinib (both agents beginning Cycle 1, D1) for which there was an analyzable PBMC sample. | percentage of cells | MEAN |
| SECONDARY | Polymorphonucler Myeloid-derived Suppressor Cells (PMN-MDSC) | At between 4 and 6 weeks, post treatment | Patients that received Vaccine (Cycle 1, Day 1) + dasatinib (Cycle 2, D1) or Vaccine + dasatinib (both agents beginning Cycle 1, D1) for which there was an analyzable PBMC sample. | percentage of cells | MEAN |
| SECONDARY | Polymorphonucler Myeloid-derived Suppressor Cells (PMN-MDSC) | At between 7 and 10 weeks, post treatment | Patients that received Vaccine (Cycle 1, Day 1) + dasatinib (Cycle 2, D1) or Vaccine + dasatinib (both agents beginning Cycle 1, D1) for which there was an analyzable PBMC sample. | percentage of cells | MEAN |
| SECONDARY | EphA2 Protein Expression in Tumor Biopsies | Up to 6 months | Results not achievable due to insufficient patient biopsy material for the assays required for this endpoint. | ||
| SECONDARY | Suppressor Cell Populations and Blood Vessels in Melanoma Tumor Biopsies | Up to 6 months | Results not achievable due to insufficient patient biopsy material for the assays required for this endpoint. | ||
| SECONDARY | CD8+ T Cells Infiltration | Up to 6 months | Results not achievable due to insufficient patient biopsy material for the assays required for this endpoint. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01876212/outcomes